Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 1:07 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 2,117 matching trials from the live ClinicalTrials.gov search.
Conditions
Non Hodgkin Lymphoma, Solid Tumor
Interventions
SB-4826, Rituximab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
1
States / cities
La Jolla, California
Conditions
Lymphoproliferative Malignancies, Acute Myeloid Leukemia
Interventions
ZEN003365
Drug
Lead sponsor
Zenith Epigenetics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Springfield, Oregon + 1 more
Conditions
Leukemia, Acute Lymphocytic (ALL), Leukemia, Myeloid, Acute(AML), Leukemia, Myeloid, Chronic(CML), Juvenile Myelomonocytic Leukemia (JMML), Hemoglobinuria, Paroxysmal Nocturnal (PNH), Hodgkin Lymphoma, Lymphoma, Non-Hodgkin (NHL), Myelodysplastic Syndrome (MDS)
Interventions
CliniMACS, Stem cell transplantation, Fludarabine, Thioplex®, L-phenylalanine mustard, Mycophenolate mofetil, Rituxan™, Alemtuzumab, Cyclophosphamide, Anti-thymocyte globulin (Rabbit), G-CSF, Muromonab
Device · Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Non-Hodgkin's B-cell Lymphoma, Leukemia, Lymphocytic, Chronic, B-Cell, Small Lymphocytic Leukemia, Diffuse Large B Cell Lymphoma, Blood Cancer, Hematological Malignancy
Interventions
MT-3724 Phase 1, MT-3724 Phase 2
Drug
Lead sponsor
Molecular Templates, Inc.
Industry
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Whittier, California • Jacksonville, Florida + 12 more
Conditions
Leukemia, Lymphoma
Interventions
anti-thymocyte globulin, filgrastim, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
Up to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
San Francisco, California
Conditions
Relapsed/Refractory Peripheral T-cell Lymphoma, Relapsed/Refractory Classical Hodgkins Lymphoma
Interventions
AZD4573
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
6
States / cities
Duarte, California • Boston, Massachusetts • Hackensack, New Jersey + 3 more
Conditions
Acute Myeloid Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma
Interventions
FT-1101, Azacitidine
Drug
Lead sponsor
Forma Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
8
States / cities
Los Angeles, California • Sarasota, Florida • Tampa, Florida + 5 more
Conditions
Fever, Sweats, and Hot Flashes, Infection, Leukemia, Lymphoma, Myelodysplastic Syndromes, Neutropenia, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
recombinant human mannose-binding lectin
Biological
Lead sponsor
Enzon Pharmaceuticals, Inc.
Industry
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Orange, California • Washington D.C., District of Columbia • Philadelphia, Pennsylvania
Conditions
CD19 Positive, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma
Interventions
Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine, Etoposide, Filgrastim, Melphalan, Rituximab, Umbilical Cord Blood-derived Natural Killer Cells
Procedure · Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Houston, Texas
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
hLL1-DOX (IMMU-115)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
6
States / cities
Newark, Delaware • Orlando, Florida • Goshen, Indiana + 3 more
Conditions
Lymphoma
Interventions
rituximab, bortezomib, gemcitabine hydrochloride, questionnaire administration
Biological · Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2023
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Conditions
Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Interventions
CliniMACS® CD34 Reagent System, Fludarabine, Melphalan, Rabbit ATG, Double Umbilical Cord Blood Transplantation, Haplo-Identical Cord Transplantation
Device · Drug · Procedure
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
B-Cell Lymphoid Malignancies, Hematologic Malignancy, Non-Hodgkin Lymphoma
Interventions
Hematopoietic Stem Cells from HLA-compatible Related, Hematopoietic Stem Cells from HLA Unrelated
Biological
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Miami, Florida
Conditions
Hodgkin's Disease, Non-Hodgkin's Lymphoma
Interventions
Vorinostat, Niacinamide, Etoposide
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2015
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma, Non-Hodgkin, Neoplasms
Interventions
Meaning-Centered Group Psychotherapy, Standard Supportive Group Psychotherapy
Behavioral
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
New York, New York
Conditions
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
ziv-aflibercept
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
25 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
New York, New York
Conditions
Medical Oncology
Interventions
Copanlisib (BAY80-6946), Itraconazole, Rifampin
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Lymphoma, Follicular, Follicular Lymphoma
Interventions
Mosunetuzumab, Polatuzumab vedotin
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma
Interventions
Ibrutinib, Idelalisib
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2016
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Conditions
AML, ALL, CLL, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Multiple Myeloma, Aplastic Anemia, Myeloproliferative Disorder
Interventions
Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Up to 65 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage I Mycosis Fungoides and Sezary Syndrome AJCC v7, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v7
Interventions
Carmustine, Laboratory Biomarker Analysis, O6-Benzylguanine
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Detroit, Michigan • Cleveland, Ohio • Columbus, Ohio
Conditions
Graft Versus Host Disease, Leukemia, Lymphoma
Interventions
rituximab, fludarabine phosphate, melphalan, sirolimus, tacrolimus, allogeneic hematopoietic stem cell transplantation, indium In 111 ibritumomab tiuxetan, yttrium Y 90 ibritumomab tiuxetan, laboratory biomarker analysis
Biological · Drug · Procedure + 2 more
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2023
U.S. locations
1
States / cities
Duarte, California
Conditions
Lymphoma
Interventions
autologous tumor cell vaccine, keyhole limpet hemocyanin, sargramostim, adjuvant therapy
Biological · Procedure
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2008
U.S. locations
1
States / cities
Omaha, Nebraska